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Hematopoietic stem cell transplantation (HSCT) is a treatment option for several mallignant and nonmalignant disorders. In autolol
gous HSCT, the stem cells are collected from the patient 
then infused back after high dose chemotherapy. In all
logeneic HSCT, the stem cells are donated from another 
individual (who may be related or unrelated and matched 
or unmatched). The hematopoietic stem cells may be obl
tained from bone marrow or peripheral blood, or harl
vested from umbilical cord blood. Allogeneic HSCT is 
further classified according to the intensity of the condil
tioning regimen. Myeloablative regimen is when supralel
thal doses of chemotherapy with or without irradiation 
are given, leading to significant toxicity and immunol
suppression. More recently, nonmyeloablative regimens 
have been used to extend transplant to older patients and 
those with colmorbidities. This approach may also be asl
sociated with less graft versus host disease (GVHD) and 
more potent graft versus malignancy effect. 
Pulmonary complications, both infectious and nonl
infectious, occur in 25%l50% of HSCT recipients, and 
are associated with significant morbidity and mortality1l3 
(Figure 1). The advances in the diagnosis and management 
of infectious pulmonary complications following HSCT 
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have increased the significance of noninfectious conditions. 
This review provides a clinical update of the main nonlinl
fectious pulmonary complications following HSCT, del
scribing the incidence, risk factors, pathogenesis, diagnosis, 
management and outcome of these conditions. 
Engraftment syndrome
Engraftment syndrome describes a clinical entity charl
acterized in its full expression by a combination of fever, 
erythrodermatous rash, and noncardiogenic pulmonary 
edema coinciding with neutrophil recovery.4 It usually 
develops within 96 hrs of engraftment.4 The syndrome 
has been described as occurring more frequently after 
autologous HSCT, with an incidence of 7–11% when 
stringent diagnostic criteria are utilized.5 A similar prel
sentation after allogeneic transplantation has been del
scribed, but must be distinguished from acute GVHD. 
The etiology of this syndrome is poorly understood. 
Release of proinflammatory cytokines during engraftl
ment is postulated to play a principal role. The use of 
granulocyte colonylstimulating factor (GlCSF) may 
increase the incidence and severity of the engraftment 
syndrome. GlCSF up regulates the production of cytol
kines (TNFlα, ILl1B, and ILl8), which increase alveol
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lar permeability and neutrophil influx.6
Specific criteria have been suggested for the diagnosis 
of engraftment syndrome following HSCT. These include 
major criteria: temperature ≥38.3ºC with no identifiable 
infectious etiology, erythrodermatous rash involving more 
than 25% of body surface area and not attributable to a 
medication, and noncardiogenic pulmonary edema manil
fested by diffuse pulmonary infiltrates consistent with the 
diagnosis and hypoxia. Minor criteria include: hepatic 
dysfunction, renal insufficiency, weight gain ≥2.5% of 
baseline body weight, and transient encephalopathy unexl
plainable by other causes. Three major or two major and 
one or more minor criteria are needed for the diagnosis of 
engraftment syndrome following HSCT.7
The prognosis of engraftment syndrome is generally 
favorable. Mild cases are managed by supportive meal
sures. Strong consideration should be given to disconl
tinue GlCSF. More severe cases, especially those with 
pulmonary involvement have dramatic response to sysl
temic corticosteroids with improvement within one day 
of treatment. Patients who require mechanical ventilal
tion have worse prognosis.4,7l9 
Diffuse alveolar  hemorrhage
The development of diffuse alveolar hemorrhage 
(DAH) as a noninfectious complication after HSCT 
was first brought to light by Robbins and colleagues 
who, in a retrospective review of 141 consecutive aul
tologous transplant recipients identified 29 patients 
(21%) with this disorder.10 The hallmark of the synl
drome was the finding of progressively bloodier return 
from bronchoalveolar lavage (BAL) in the absence of an 
identifiable respiratory tract infection. Since the initial 
description, DAH has been reported by multiple other 
groups, albeit with a significantly lower incidence rangl
ing between 2% and 14% with a mean of 5% of HSCT 
recipients.11 The incidence among autologous and allol
geneic recipients appears to be equivalent.11 In a study 
of 48 patients with DAH, the incidence was 4% of all 
HSCT recipients. 52% of the patients had autologous 
HSCT and 48% were allogeneic HSCT recipients. 
The stem cells were from peripheral blood in 67% of 
the patients.12 Risk factors for DAH following HSCT 
include age greater than 40 years, total body irradiation, 
transplantation for solid tumors, and the presence of 
high fevers, severe mucositis, leukocyte recovery, and rel
nal insufficiency. Although thrombocytopenia is coml
mon, platelet counts are not lower than those found in 
patients without DAH and aggressive platelet transful
sion does not result in improvement in respiratory stal
tus.10 There is also no relation between DAH and type 
of preparatory regimen, whether it is reduced intensity 
or myeloablative.13
The pathogenesis of DAH in HSCT recipients rel
mains obscure. Postmortem investigations have shown 
that the majority of patients with DAH have evidence 
of diffuse alveolar damage.10,11,14 It is possible that DAH 
is part of a spectrum of acute lung injury induced by 
conditioning chemotherapy, radiation, or occult infecl
tion. The fact that many cases occur at the time of enl
graftment suggests that neutrophil influx into the lung 
may accentuate the injury and in some way precipitate 
alveolar hemorrhage. 
DAH is most commonly observed within the first 
month after HSCT ( a median of 23 days ) often during 
the periengraftment phase, but later onset is encounl
tered in up to 42% of cases.11 Patients present with dysl
pnea, nonproductive cough, fever, and diffuse pulmol
nary infiltrates, but hemoptysis is notably rare. Intensive 
care unit admission and mechanical ventilation are 
required by the majority of patients. Radiological findl
ings are usually diffuse interstitial, alveolar or ground 
glass changes that are more prominent in the perihilar 
areas and lower lobes (Figure 2). The radiological findl
ings may appear up to 3 days prior to clinical diagnosis 
of DAH. The diagnosis is usually made by BAL that 
reveals progressively bloodier lavage fluid return from 
at least three separate subsegmental bronchi. However, 
it is possible to have DAH with nonbloody BAL fluid, 
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Figure 1. The time line of the main pulmonary complications following HSCT.                
HSV: herpes simplex virus, HZV: herpes zoster virus, CMV: cytomegalovirus, RSV: 
respiratory syncytial virus, CHF: congestive heart failure, BO: bronchiolitis obliterans, 
VOD: veno-occlusive disease, ES: engraftment syndrome, DAH: diffuse alveolar 
hemorrhage, BOOP: bronchiolitis obliterans organizing pneumonia, IPS: idiopathic 
pneumonia syndrome, PTLPD: post transplant lymphoproliferative disorder
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especially if the procedure is done few days after the onl
set of symptoms.14 The presence of greater than 20% 
hemosiderinlladen macrophages in BAL fluid is an all
ternative diagnostic criterion, but because it may take 
48l72 hours for this finding to appear.11,12 
The following diagnostic criteria have been sugl
gested to diagnose DAH following HSCT: 1) evidence 
of widespread alveolar injury manifested by multilobar 
pulmonary infiltrates, symptoms and signs of pneumol
nia, and abnormal physiology with widened Ala gradil
ent, 2) BAL showing progressively bloodier return from 
three separate subsegmental bronchi, or more than 20% 
hemosidrenlladen macrophages on examination of the 
BAL fluid, or if a surgical lung biopsy is performed, 
more than 30% of the alveolar surface of the examined 
lung tissue is covered by blood, and 3) absence of infecl
tion compatible with the diagnosis.11 
There are no prospective randomized trials to adl
dress the management of DAH following HSCT. 
Retrospective case series and anecdotal reports suggest 
that highldose corticosteroids (500l1000 mg per day 
of methylprednisolone for 3l4 days followed by taper 
over 2l4 weeks) may improve the survival rate.15l17 One 
study suggested that the addition of an antifibrinolytic 
agent such as aminocaproic acid was associated with 
lower mortality and no side effects.18 With supportive 
therapy alone, mortality rates in patients with DAH of 
74l100% have been reported.10, 11,15 A series from the 
Mayo Clinic suggested that the mortality associated 
with DAH is lower than previously reported (48%) 
and that autologous HSCT, onset within the first 30 
days of transplantation and lack of mechanical ventil
lation were associated with favorable outcome.12 The 
cause of death in patients with DAH following HSCT 
is usually a result of superimposed multi organ failure 
or sepsis rather than respiratory failure from refractory 
alveolar hemorrhage.11 Long term survivors of DAH 
following HSCT have normal lung function.17
Idiopathic pneumonia syndrome
Idiopathic pneumonia syndrome (IPS) is another iml
portant cause of nonlinfectious diffuse lung injury foll
lowing HSCT. A National Institutes of Health workl
shop defined IPS as “diffuse lung injury occurring after 
marrow transplant for which an infectious etiology is 
not identified”.19 This workshop put forward the followl
ing diagnostic criteria for IPS: 1) evidence of widespread 
alveolar injury as manifested by multilobar infiltrates, 
symptoms and signs of pneumonia, and increased Ala 
gradient and/or restrictive lung disease based of pulmol
nary function tests. 2) absence of lower respiratory tract 
infection after appropriate evaluation that includes 
BAL that is negative for bacterial and nonlbacterial 
pathogens, lack of improvement with broad spectrum 
antibiotics, and a second confirmatory test within 2l14 
days. 3) If lung biopsy is performed it usually reveals 
one of two patterns: diffuse alveolar damage or interl
stitial pneumonitis.19 Applying these criteria to a retrol
spective review of 1165 consecutive patients at the Fred 
Hutchinson Cancer Research Center, Kantrow and 
colleagues found that the incidence of IPS in the first 
120 days was 7.6% after allogeneic HSCT and 5.7% 
after autologous procedures.20 In a review of 12 studl
ies (4496 HSCT recipients) the incidence of IPS was 
a mean of 10% (range 2l17%). The condition was more 
common following allogeneic HSCT (10.6%) as coml
pared to autologous HSCT (5.8%).21
Risk factors for developing IPS following HSCT 
include older age, lower preltransplantation perforl
mance status, transplantation for a malignancy other 
than leukemia, highlintensity conditioning regimens, 
total body irradiation, highlgrade acute GVHD, and 
methotrexate based GVHD prophylaxis.21l23 A study 
focusing exclusively on allogeneic HSCT recipients 
A
B
Figure 2A,B. Chest radiograph and chest CT scan image showing 
bilateral diffuse alveolar infiltrates in a patient with DAH 
following allogeneic HSCT.
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found that the incidence of IPS was significantly lower 
after nonmyeloablative versus conventional highldose 
conditioning regimens (2.2% vs 8.4%), suggesting 
that IPS may be the result of toxicity from intensive 
chemotherapy and radiation.22 The occurrence of IPS 
after both allogeneic and autologous HSC transplanl
tation provides further evidence that conditioninglrel
lated toxicities are principally involved. On the other 
hand, the association of IPS with acute GVHD after 
allogeneic transplantation suggests that alloreactive 
T cell injury may be a contributing factor in this setl
ting. It is also possible that some cases of “idiopathl
ic” pneumonia actually represent acute lung injury 
secondary to an occult infection. Murine models of 
IPS following allogeneic HSCT suggest that there 
are two pathways for immune mediated lung injury: 
one involving soluble inflammatory effectors such 
as TNFlα, and the other driven by antigen specific, 
donor Tlcell effectors. Both pathways are associated 
with increased BAL concentrations of inflammatory 
mediators such as TNFlα, TNFRI, TNFRII, ILl
6, ILl8, slCD14, and MCPl1. These, in turn, trigl
ger the acute lung injury associated with IPS.24,25 
Patients with IPS usually present with dyspnea, fever, 
nonproductive cough, increasing oxygen requirements, 
and diffuse radiographic infiltrates. In the study from 
Seattle, the median time to onset of IPS was 21 days 
after transplantation. Other studies have reported 
a more delayed median onset, between 42 and 49 
days following HSCT.19,20 The clinical course of IPS 
is typically rapid, with up to twolthirds of patients 
progressing within several days to respiratory failure 
requiring mechanical ventilation.20 Collective mortall
ity in six of the larger clinical series was 74% (range 
60l86%).21 Mortality in patients with IPS is primarily 
related to progressive respiratory failure. Factors that 
predict mortality include the need for mechanical venl
tilation and higher serum creatinine level at the onset 
of IPS.21,22
Beyond supportive care, there is no proven treatl
ment for IPS. Highldose corticosteroid therapy does 
not appear to be of benefit.20,22 The administration 
of etanercept, a soluble TNFlα–binding protein, 
was well tolerated by three pediatric allogeneic HSC 
transplant recipients with IPS and was associated 
with significant improvement in pulmonary function 
within the first week of therapy.26 In another recent 
report,15 HSCT recipients with IPS were treated with 
combination of etanercept at a dose of 0.4 mg/kg 
(maximum dose 25mg), twice weekly for maximum 
total of 8 doses, combined with corticosteroids (2 mg/
kg per day) for 7 days then tapered as clinically indil
cated. This treatment was well tolerated. Two third of 
the patients had complete response a median of 7 days 
after initiation of therapy.24 These clinical reports are 
encouraging and should prompt clinical trials to prove 
the efficacy of this therapy. In the meantime, etanerl
cept may be considered in patients with IPS following 
allogeneic HSCT. 
Table 1 summarizes the similarities and differences 
between the 3 main noninfectious causes (engraftment 
syndrome, DAH, and IPS) of diffuse lung injury foll
lowing HSCT.
Delayed pulmonary toxicity syndrome
The term “delayed pulmonary toxicity syndrome” del
scribes a form of mildltolmoderate pulmonary injury 
observed after highldose chemotherapy and autologous 
Table 1. Comparison of the characteristics of the main non-infectious causes of acute lung injury following HSCT.
Feature Engraftment syndrome DAH IPS
Incidence Autologous > allogeneic Autologous = allogeneic Allogeneic > autologous
Onset Early/acute Early/acute Late/subacute
Relation to stem cell 
engraftment Within 96 hr of engraftment
Relation to engraftment is less 
definite No relation
Characteristic clinical 
feature Systemic manifestations Bloody BAL Progressive respiratory failure
Pathology Diffuse alveolar damage. G-CSF plays a role
Diffuse alveolar damage with 
release of several cytokines
Diffuse alveolar damage. TNF-α 
plays a role. 
Response to 
corticosteroids Excellent response Moderate response Poor response
Prognosis Favorable prognosis
Less favorable prognosis. 
Usually die with multi-organ 
failure and sepsis
Poor prognosis usually die with 
respiratory failure
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HSCT for breast cancer.27 In contrast to IPS, this synl
drome presents at a later time point, is generally responl
sive to corticosteroid therapy, and has a better prognosis. 
In a study of 45 consecutive women who received highl
dose chemotherapy with cyclophosphamide, cisplatin, 
and bischloroethylnitrosourea (BCNU) followed by 
autologous HSCT, 26 patients (58%) developed sympl
tomatic pulmonary toxicity with a mean onset of 10 
weeks after transplantation.28 Symptoms are nonspecific 
and include dyspnea on exertion, nonproductive cough, 
and fever. Pulmonary function testing reveals a marked 
reduction in the diffusing capacity associated with a 
mild to moderate restrictive pattern. Ground glass opacl
ities are the most common radiographic findings deml
onstrated on CT scan imaging, but these abnormalities 
may be absent or delayed in up to onelthird of patients. 
Delayed pulmonary toxicity syndrome likely reprel
sents a manifestation of chemotherapylinduced lung 
injury. In support of this therapy, lung pathology specl
imens in 10 patients with this syndrome demonstratl
ed findings consistent with pulmonary drug toxicity, 
including alveolar septal thickening, interstitial fibrol
sis, and type II pneumocyte hyperplasia.27 Moreover, 
in a study that randomized patients to highldose verl
sus standard chemotherapy before autologous HSCT, 
the incidence of delayed pulmonary toxicity syndrome 
was 72% in the highldose group and only 4% in the 
group receiving standard therapy.29 Two of the chemol
therapeutic agents used in the conditioning regimen 
administered to patients with this syndrome–BCNU 
and cyclophosphamide–have been associated with 
lung toxicity. Although the highldose chemotherapy 
regimens associated with delayed pulmonary toxicity 
syndrome utilized doses of BCNU below the threshl
old typically associated with pulmonary toxicity, it is 
likely that the risk of toxicity is enhanced by synergism 
with concurrently administered cyclophosphamide. 
The nitric oxide pathway may also play a role in the 
pathogenesis of this syndrome. A study of 20 patients 
with breast cancer who developed delayed pulmonary 
toxicity syndrome following high dose chemotherapy 
and autologous HSCT showed that there is increase 
in the concentration of exhaled nitric oxide following 
transplant as compared to preltransplant values and 
this findings correlated very well with reduction in difl
fusing capacity.30
Patients with delayed pulmonary toxicity syndrome 
respond well to systemic corticosteroid therapy with 
improvement in their symptoms, radiological and 
physiological findings. Typically, the dose of corticol
steroids is equivalent to prednisone 60mg daily that is 
tapered over two months.28 
Bronchiolitis obliterans
Bronchiolitis obliterans (BO) is the most important 
late nonlinfectious pulmonary complication followl
ing HSCT. This condition is characterized by the new 
onset of air flow obstruction (AFO) following HSCT. 
Due to the lack of a standardized definition, the incil
dence of BO varies widely in the literature. The reportl
ed incidence ranges from 0 to 48%. In a review of 2152 
allogeneic HSCT recipients reported in nine studies, 
the average incidence of BO was 8.3%.21 In a report 
from Seattle, the incidence of BO in 1131 allogeneic 
HSCT recipients was 26%; however, in patients with 
chronic GVHD, the incidence of BO was 32%.31 The 
International Bone Marrow Transplantation Registry 
(IBMTR) has reported that the incidence of BO was 
1.7% in the two years following matched sibling HSCT 
of 6275 patients.32 One report specifically commented 
on the incidence of BO following peripheral blood stem 
cell transplantation and showed that there was threel
fold increase in the risk of BO compared with bone 
marrow transplantation (hazard ratio 3.35; 95% conl
fidence interval (CI) 1.79–6.27; P<.0002).32 Yoshihara 
et al33 reported that the incidence of BO following 
nonlmyeloablative HSCT was 2.3% compared with 
17% following conventional myeloablative HSCT. The 
difference between these two groups was statistically 
significant, but the clinical course and outcome of BO 
were similar. In general, BO does not develop following 
autologous HSCT. There are only a few cases reported 
in the literature of BO developing following autologous 
HSCT with fatal outcome.34,35 Furthermore, there are 
very few reports of BO proven by lung biopsy developl
ing in patients who received umbilical cord blood stem 
cell transplantation.36,37
Several risk factors have been suggested as prel
disposing to BO following HSCT. The presence of 
chronic GVHD is the most important association with 
BO. Earlier studies suggest that BO does not develop 
in patients without evidence of chronic GVHD.38,39 
However, more recent studies from large HSCT centers 
report that BO may develop in a small percentage of pal
tients who do not have manifestations of GVHD.32,40 
The risk of BO appears to be higher in those with prol
gressive chronic GVHD (which evolves without hiatus 
from active acute GVHD) as compared to those with 
quiescent chronic GVHD (that develops after an inl
terval of response to treatment of acute GVHD) or de 
novo chronic GVHD (in patients who never had acute 
GVHD). In the study by Chien et al40 the adjusted relal
tive risk (95% CI; P value) for GVHD types associated 
with AFO was: 1.3 (0.8l2.0; 0.3) with acute GVHD; 
1.5 (0.8l2.0; .04) with de novo chronic GVHD; 1.6 
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(1.3l2.4; <.001 ) with quiescent chronic GVHD; and 
1.9 (1.4l2.4; <.001) with progressive chronic GVHD. 
In the majority of reports, acute GVHD alone does not 
appear to significantly increase the risk of BO.31,40l42
Other frequently observed risk factors for BO inl
clude: an older age of the recipient (>20 yrs); the presl
ence of AFO (forced expiratory volume in one second 
(FEV1)/forced vital capacity (FVC) <0.7) prior to 
HSCT; and respiratory viral infections, such as influl
enza, parainfluenza and respiratory syncytial virus, in 
the first 100 days following HSCT.31,40 Recent reports 
also suggest that biochemical (such as low preltransl
plant serum surfactant D protein level) and genetic 
factors (such as NOD2/CARD15 polymorphism) 
may predispose HSCT recipients to BO, and detecl
tion of these factors may lead to earlier recognition of 
these patients.43,44
The pathogenesis of BO following HSCT is not 
well defined. Several theories have been suggested, all
though none of them have satisfactorily explained the 
pathogenesis of BO. One of these theories explains BO 
as a result of a lung injury precipitated by the condil
tioning regimen. This is based on the higher incidence 
of BO in busulfanlbased conditioning regimen45,46 and 
the apparent lower incidence of BO in nonlmyeloabl
lative HSCT compared with conventional regimen.33 
Another proposed mechanism focuses on the developl
ment of BO due to infectious etiology. This is supported 
by various observations including the association of BO 
with low serum immunoglobulins secondary to slow rel
constitution of B cells following transplantation.41,47,48 
This deficiency may be associated with abnormal local 
defense mechanisms in the lung, predisposing them to 
infections that lead to BO. This is also supported by 
the observation that allogeneic HSCT recipients who 
develop parainfluenza and respiratory viral infections 
early in the course following transplantation are at an 
increased risk of developing BO.40 Although, infection 
may still be an important mechanism in the pathogenl
esis of BO, there is lack of exclusive evidence to prove 
this theory. Recurrent microaspirations have been sugl
gested as one of the mechanisms of BO following lung 
transplantation.49l51 Recurrent aspiration due to esophl
agitis associated with chronic GVHD may promote 
chronic inflammation and recurrent infections in the 
lower airways that may lead to BO. 
The most important mechanism contributing to BO 
is probably an alloreactive immune process in which the 
donors Tllymphocytes target the epithelial cells of the 
bronchioles, leading to the inflammatory reaction seen 
in BO. This mechanism is evident from the exclusive 
occurrence of BO following allogeneic HSCT, and the 
strong association between BO and chronic GVHD. 
Indeed, some authors suggest that BO is a manifestal
tion of chronic GVHD.52 Also, the reported stabilil
zation of BO in some HSCT recipients by systemic 
corticosteroids and intensification of immunosuppresl
sive therapy supports the theory that suppression of 
Tlcells may decrease the manifestation of BO followl
ing HSCT. It also suggests that depletion of T lyml
phocytes may decrease the incidence of BO in these 
patients.53 A welllcharacterized mouse model studied 
BO caused by low dose allogeneic T cell infusion in 
bone marrow transplant setting. Examination of the 
lungs after 2 months showed histological evidence of 
BO with extensive perivascular and peribronchiolar inl
flammation consistent with donor CD4+ and CD8+ T 
cells, B cells, macrophages, neutrophils and fibroblasts. 
At the same time, features of GVHD in the skin, liver 
and colon were mild to moderate.54 These immune 
mechanisms are thought to trigger inflammatory reacl
tions that lead to BO. These inflammatory reactions 
are characterized by an increase in cytokines, such as 
ILl1, ILl6, ILl8, ILl18 and TNFlα.55,56 
BO is a late complication of allogeneic HSCT 
and usually presents after the first 100 days following 
transplantation.38,41,57l61 Although there are reports of 
BO as early as 30 days following HSCT, 80% of cases 
present between 6 and 12 months postltransplantal
tion.47,62 The presentation of BO is usually insidious. 
In total, 23% of patients describe antecedent upper 
respiratory tract symptoms.58 The main symptoms asl
sociated with BO are dry cough (60l100%) and dysl
pnea (50l70%).39, 47,58,63 Wheezing and sinusitis are 
other frequent symptoms. Fever is rare unless there is 
a concomitant infectious process. Approximately 20% 
of patients are asymptomatic and the diagnosis is susl
pected based on pulmonary function test findings.58 
In the advanced stages of BO, the patients are physil
cally limited due to severe obstructive airway disease 
and may require home oxygen therapy. Some patients 
may develop features of bronchiectasis with recurrent 
respiratory tract infections and colonization of the airl
ways by Pseudomonas spp., Staphylococcus aureus and, 
occasionally, Aspergillus species.
The clinical course of BO is variable. The majority 
of patients have a slow progressive AFO, with episodes 
of acute exacerbation of AFO. In the minority of pal
tients, the AFO progresses rapidly and patients develop 
respiratory failure within a few months. However, some 
patients may have stabilization or even improvement in 
the AFO.64,65
In the early stages of BO, the chest radiograph is 
normal. The presence of parenchymal changes suggests 
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an infection or an unrelated process. As BO becomes 
more advanced, there are signs of hyperinflation on 
the chest radiograph and, later, there are changes conl
sistent with bronchiectasis with dilated and thickened 
bronchi and areas of scarring. Pneumothorax, pneumol
mediastinum, and pneumopericardium may develop 
in advanced cases, and are usually associated with sigl
nificant morbidity and mortality.38,66,67 Highlresolution 
computed tomography (HRCT) of the chest is much 
more sensitive in detecting signs of BO and is the ral
diological procedure of choice in evaluating these pal
tients.68,69 While the study may still be normal in the 
early stages of BO, it usually shows signs of hyperinflal
tion with areas of decreased attenuation. Bronchiectasis 
is seen in advanced cases. However, the most common 
radiological sign of BO on HRCT of the chest is the 
presence of air trapping during the expiratory phase of 
imaging. These views show areas of hypoattenuation 
that correspond to obstructed airways interspaced with 
areas of ground glass appearance corresponding to the 
pulmonary lobules with patent airways. This ‘‘mosaic’’ 
appearance is highly suggestive of BO, and has sensitivl
ity and specificity in the diagnosis of BO with ranges 
between 74l91% and 67l94%, respectively.70,71 (Figure 
3) In addition, HRCT of the chest is helpful in excludl
ing colexisting conditions such as infections, bronchil
olitis obliterans organizing pneumonia (BOOP), or 
idiopathic pneumonia syndrome that are usually assol
ciated with parenchymal infiltrates.65 In summary, it is 
recommended that a HRCT of the chest with inspiral
tory and expiratory views be performed on all patients 
under evaluation for BO following HSCT.
Spirometry is the main study used to diagnose 
and followlup patients with BO following HSCT. 
Spirometry usually shows evidence of new AFO with 
reduction in forced expiratory volume in the first second 
(FEV1) and FEV1 to forced vital capacity (FVC) ratio 
(FEV1/FVC). However, there has been a lack of conl
sensus on the spirometric criteria for the diagnosis of 
BO following HSCT. Recently, the National Institutes 
of Health (NIH) sponsored a consensus development 
project for clinical trials on chronic GVHD.72 The 
workshop considered BO as the only diagnostic manil
festation of chronic GVHD in the lung, and suggested 
that the diagnosis of BO is made when: 1) there is evil
dence of AFO with FEV1/FVC <0.7 and FEV1 <75% 
of predicted; 2) there is evidence of air trapping or small 
airway thickening or bronchiectasis on HRCT of the 
chest with inspiratory and expiratory cuts, residual voll
ume on PFT >120% of predicted or pathological conl
firmation of constrictive bronchiolitis; and 3) absence of 
infection in the respiratory tract documented by clinical 
symptoms, radiological studies or microbiological cull
tures, obtained by sinus aspirate, upper respiratory tract 
viral screen, sputum culture or BAL.72 Table 2 proposes 
diagnostic criteria of BO following HSCT that are 
based on clinical features, radiological and spirometric 
studies, and absence of infectious processes.73
Bronchoscopy has a limited role in the diagnosis of 
BO following HSCT. BAL is mainly carried out to rule 
out an infectious process in HSCT recipients who presl
ent with respiratory symptoms suggestive of BO. This 
is especially the case when there are infiltrates on chest 
radiograph or HRCT of the chest, or in the presence 
of fever. The main infections to be considered in this 
setting, and in which BAL may be useful, are viral infecl
tions such as cytomegalovirus (CMV), respiratory synl
cytial virus, influenza, parainfluenza, or herpes simplex 
virus. In addition, fungal infections and Pneumocystis 
jiroveci need to be considered if the patient is on systeml
ic corticosteroids and/or immunosuppressive therapy.74 
BAL has also been studied to evaluate the cellular and 
chemical profile in patients with BO following HSCT. 
Transbronchial biopsy is generally not recommendl
ed for the diagnosis of BO following HSCT. This is due 
to the fact that the disease is patchy and peripheral, and 
the biopsy samples obtained by this procedure are usul
ally too small to show bronchiolar pathology. If histol
logical confirmation of BO is necessary, then the best 
approach is a surgical lung biopsy obtained by videolasl
sisted thoracoscopy. However, this procedure is rarely 
indicated for the diagnosis of BO following HSCT 
in clinical practice. Yousem52 reviewed the histological 
findings of lung biopsies in 17 HSCT patients with 
GVHDlrelated pulmonary disease. Five patients had 
Figure 3. High resolution chest CT image showing hyperinflation 
with patchy ground glass areas (white arrow) and mild 
bronchiestasis (black arrow) consistent with bronchiolitis 
obliterans.
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BO, and the biopsies showed cicatricial BO, in which 
the lumens of airways were obliterated by dense fibrous 
scar tissue. Some of these airways displayed eccentric 
subepithelial fibrous plagues. The epithelial cells were 
flattened at some locations, while other sites displayed 
metaplasia or hyperplasia. There was peribronchiolar 
mononuclear cellular inflammation, but no alveolar or 
interstitial involvement. The author’s theory on the sel
quence of events leading to BO in these patients is that 
infiltration of the submucosa of the smaller airways by 
lymphocytes occurs. These cells migrate through the 
basement membrane of respiratory epithelium leadl
ing to epithelial cell necrosis and areas of ulceration. 
Myofibroblasts then grow through these denuded areas 
and deposit young collagen, creating intraluminal granl
ulation tissue and scarring.
In general, the management of BO is difficult as the 
pathogenesis is incompletely understood and “treatl
ment” does not result in reversible improvement of lung 
function. Goals of therapy may be directed towards 
stabilization at best. The treatment approaches are 
based on small uncontrolled trials and expert opinions. 
However, in general, the management of BO is simil
lar to that of chronic GVHD and consists of high dose 
systemic corticosteroids and reinstitution or augmenl
tation of immunosuppressive therapy. Systemic cortil
costeroids are suggested in the form of prednisone at 
1l1.5 mg/ kg daily (up to 100 mg/day) for 2l6 weeks. If 
there is clinical and physiological stabilization, the dose 
is tapered every 2 weeks over 3l12 months. This regil
men is based on expert opinions and small case series 
rather than controlled trials.39,57,58,60,75l78 The immunol
suppressive agents used are similar to those used in the 
treatment of chronic GVHD, namely cyclosporine A or 
tacrolimus.39,60,61,65,75 It is possible that early treatment 
may prevent the progression of AFO.31 Conversely, it 
was observed that the rapid taper of cyclosporine A 
(for prophylaxis against GVHD) was associated with 
increased late noninfectious pulmonary complications, 
including BO.79 This treatment regimen is recommendl
ed for 3l12 months; however, some studies suggest 
that further improvement is unlikely after 9 months of 
treatment.75 Also, intravenous immunoglobulins have 
been given to patients with BO, with no proven benl
efit.80 Based on the experience using macrolides in the 
treatment of diffuse panbronchiolitis, cystic fibrosis and 
treatment of BO following lung transplantation, this 
class of medications is increasingly considered in the 
management of BO following HSCT.81l84 Macrolides 
apparently downregulate prolinflammatory cytokines, 
such as TNFlα, so they may decrease the inflammatory 
reaction that leads to BO.85 In a report of eight patients 
with BO, azithromycin was added at a dose of 250 mg 
three times a week for 12 weeks, and the authors rel
ported an average of 281 mL (20.5%) improvement in 
FEV1.86 However, the value and longlterm risk of addl
ing such agents to the treatment regimen of patients 
with BO following HSCT is still not known, and it apl
pears that the response to this treatment is variable. 
There are reports on the addition of inhaled cortil
costeroids to the standard immunosuppressive regimen 
in the management of BO following lung transplantal
tion.87,88 This led some investigators to use highldose inl
haled corticosteroids in the management of patients with 
Table 2. Suggested diagnostic criteria of BO following HSCT.
1. Allogeneic HSCT
2. Chronic GVHD
3. Insidious onset of dyspnea, cough and wheezing usually after 100 days following transplantation
4. Normal chest radiograph
5. 
HRCT of the chest (with inspiratory and expiratory 
views) showing areas of air trapping on expiratory 
views (mosaic pattern), hyperinflation, micronodular 
changes, or bronchial dilatation, with no parenchymal 
involvement.
6. 
PFT showing new onset of airflow obstruction (FEV1/
FVC <0.7 and FEV1 <75% of predicted), not responsive to 
bronchodilators
7. 
Exclusion of an infectious process by appropriate 
radiological, serological and microbiological studies 
(obtained by sinus aspirate, upper respiratory tract viral 
screen,  sputum culture or BAL).
Table 3. Suggested approach to the management of BO following 
HSCT.
1. Confirm the diagnosis of BO- (see Table 2)
2. Systemic corticosteroids (Prednisone 1-1.5 mg/kg/day). Taper gradually over 6-12 months
3. Immunosuppressive therapy (such as cyclosporine A or tacrolimus)
4. Maintenance macrolide treatment
5. Inhaled bronchodilators
6. Prophylactic therapy against P jiroveci, fungi and CMV
7. Anti-reflux measures
8. Consider inhaled corticosteroids
9. Consider extracorporeal photodynamic therapy
10. Consider intravenous immunoglobulins
11.
In advanced cases:
- long term oxygen therapy
- outpatient pulmonary rehabilitation
- consider lung transplantation
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BO following HSCT. A recent retrospective analysis by 
Bashoura et al89 described a series of 17 adult patients to 
evaluate the efficacy of highldose inhaled corticosteroids 
in the treatment of BO following HSCT. All patients rel
ceived inhaled fluticasone propionate 500l940 mcg two 
times daily. Symptoms of airway obstruction improved 
and FEV1 stabilized 3l6 months after treatment. The 
authors concluded that highldose inhaled corticostel
roids may be effective in the treatment of BO. A prol
spective evaluation of this therapy is warranted. There 
are also limited studies on the combination of inhaled 
corticosteroids and longlacting B2 agonist in patients 
with BO following HSCT. Patients should be treated 
with shortlacting bronchodilators if they are symptoml
atic and during acute exacerbations of respiratory sympl
toms; however, most of the studies show that the reversl
ibility in AFO with these agents is negligible.57,58,62
Extracorporeal photodynamic (ECP) therapy is anl
other immunotherapeutic modality that has been used 
in the treatment of chronic GVHD and BO. This therl
apy is commonly used in the management of cutaneous 
Tlcell lymphoma, scleroderma and other autoimmune 
disorders. It involves extracorporeal exposure of periphl
eral blood mononuclear cells to photoactivated 8lmel
thoxypsoralen, by exposure to ultraviolet A light, foll
lowed by relinfusion of the treated cells.90 It is believed 
that the photoactivated 8lmethoxypsoralen binds to 
DNA, leading to initiation of apoptosis, and that it has 
a selective effect on autoreactive T cells.91 These obserl
vations led to the use of ECP in the management of 
refractory acute and chronic GVHD. Several studies 
reported improvement in skin, mucus membrane, liver 
and pulmonary GVHD, resulting in fewer symptoms 
and tapering or discontinuation of immunosuppresl
sive therapy.92 The role of ECP in the management of 
BO following HSCT has not been well studied. The 
benefits are limited to case reports or small numbers of 
cases in small trials.93,94 
There are a few reports that suggest treating BO 
using antilTNFlα monoclonal antibodies (such as 
infliximab);95 however, there are no adequate data on 
the effectiveness of this therapy. A recent case report 
highlighted the use of Imatinib mesylate 400 mg/day 
in a patient with CML who developed BO following 
HSCT. The authors reported improvement in pulmol
nary symptoms during the first 1 to 2 months of imal
tinib treatment, with gradual elimination of the need 
for oxygen, a return to normal ambulation, and conl
siderable improvement in exercise tolerance.96 Other 
agents that are used for treatment of skin and intestinal 
manifestations of chronic GVHD such as alefacept, dal
cluzimab, or rituximab may play a role in stabilizing BO 
following HSCT, although these agents have not been 
specifically investigated for this purpose.97,98 
Supportive treatment is essential in the managel
ment of patients with BO following HSCT. Infectious 
processes should be excluded prior to starting immunol
suppressive therapy. Once treatment is started, patients 
should be maintained on appropriate prophylactic meal
sures against P jiroveci. Prophylaxis against fungi and 
CMV should be considered in highlrisk patients. In 
addition, appropriate vaccinations including against inl
fluenza and pneumococcus are recommended. Prompt 
treatment of pulmonary infections is essential, since 
these tend to worsen the course and outcome of BO. 
Patients with advanced BO may require longlterm 
oxygen therapy and may benefit from outpatient pull
monary rehabilitation. There are a few reports of lung 
transplantation in patients with advanced BO with enl
couraging results.99 Table 3 summarizes a management 
approach to patients with BO following HSCT.73
BO following HSCT is a progressive disease that 
leads, in the majority of patients, to irreversible AFO. 
The decline in lung function is usually slow over sevl
eral months to years. During this course there may be 
exacerbations that are associated with temporary worsl
ening of the lung function. Some patients may have a 
rapidly progressive AFO that leads to respiratory faill
ure. Aggressive therapy results in improvement of lung 
function in only 8l20% of patients.33,46,75,100 The best 
expectations in the management of patients with BO 
are to stabilize and prevent further drops in FEV1. The 
attributable mortality of BO following HSCT was, 
in one large study, 9% at 3 years, 12% at 5 years, and 
18% at 10 years.40 While the attributable mortality, in 
those with associated chronic GVHD was 22% at 3 
years, 27% at 5 years, and 40% at 10 years.40 Patients 
with advanced BO usually die from pneumonia.60,75,76 
Factors that are associated with increased mortality rel
lated to BO following HSCT include rapid deterioral
tion of FEV1 (more than 10% annually), age >60years, 
progressive chronic GVHD, underlying disease relapse, 
and history of respiratory viral infection.32,40,47 In addil
tion, the prognosis of BO is worse if the patients do 
not respond to the primary treatment regimen.21 The 
prognosis of BO appears not to be influenced by the 
presence of AFO prior to transplantation, the source of 
stem cells, degree of matching, CMV serologic status, 
or type of GVHD prophylaxis.40 
Bronchiolitis obliterans organizing pneumonia
Bronchiolitis obliterans organizing pneumonia is a 
specific inflammatory condition that develops followl
ing HSCT. The term bronchiolitis obliterans organizl
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ing pneumonia (BOOP) following HSCT is commonly 
confused with bronchiolitis obliterans (BO). However 
these are two different entities with characteristic clinil
cal, radiological and pathological findings. Table 4 suml
marizes the characteristics of BO and BOOP following 
HSCT.101 BOOP has been described following autolol
gous and allogeneic HSCT, although more frequently 
following the later. The incidence following allogeneic 
HSCT ranges between 0.9l10.3%.79,102 In the largest 
series of histologically proven BOOP, the incidence foll
lowing allogeneic HSCT was 0.9%.102 Predictors of the 
development of BOOP were primary diagnosis of leukel
mia, radiation containing preparative regimens and the 
presence of acute and chronic GVHD. The strong assol
ciation between BOOP and acute and chronic GVHD 
suggests that the donor Tlcell mediated immune rel
sponse against the recipient lung tissue may play a role in 
the pathogenesis of BOOP in these patients. Strategies to 
deplete Tl cells may prevent BOOP in allogeneic HSCT 
recipients.53 BOOP following autologous HSCT is rare 
and may be related to infections or medications. 
BOOP usually develops earlier than BO followl
ing HSCT. The onset of BOOP ranged from 5l2800 
days, with a median of 108 days in one study.102 The 
clinical presentation is usually acute or subacute with 
2 weeks of fever, nonproductive cough, and dyspnea. 
There are rales and occasionally inspiratory squeak on 
physical examination. Radiologically, there are patchy 
(multifocal, diffuse or focal) consolidations that tend 
to be peripheral and/or peribronchovascular. In addil
tion, there may be ground glass opacities or nodular lel
sions.102 Pulmonary function tests typically show mild 
to moderate restrictive pattern and characteristically 
low diffusing capacity. Usually there is no airflow obl
struction. Bronchoscopy is very useful in patients with 
BOOP to exclude other conditions such as infections. 
BAL fluid reveals lymphocytosis with low CD4/CD8 
ratio.103 Histological confirmation is usually necessary, 
and can be made by transbronchial biopsies, however 
most patients require surgical lung biopsy by videolasl
sisted thoracoscopy. Pathologically, BOOP is characterl
ized by patchy distribution of plugs of granulation tisl
sue that fill the lumens of the distal airways extending 
to the alveolar ducts and spaces and are associated with 
chronic interstitial inflammation. Contrary to BO, pal
tients with BOOP following HSCT have more favorl
able response to systemic corticosteroid therapy with 
initial dose of prednisone 1mg/kg daily then tapered 
over 3l6 months.102 In 78% of patients, BOOP either 
resolves or remains stable. Patients who progress on 
corticosteroids therapy usually die of respiratory faill
ure.102 The case fatality of BOOP following HSCT has 
been reported to be 19%.104 
Other nontinfectious pulmonary complications
Pulmonary veno-occlusive disease
Pulmonary venolocclusive disease is a rare complication 
after both autologous and allogeneic HSCT.105,106 This 
process is characterized by intimal proliferation and fil
Table 4. Comparison between bronchiolitis obliterans and bronchiolitis obliterans organizing pneumonia.
Features Bronchiolitis obliterans BOOP
Incidence 0-48% <2%
HSCT Allogeneic Allogeneic and autologous
Onset following HSCT Late (around 1 year) Usually in the first 100 days
Clinical presentation Insidious; dyspnea, cough, wheezing Acute; dyspnea, cough, fever
Radiological findings Normal; hyperinflation, air trapping, bronchiectasis
Patchy consolidation (usually peripheral), ground 
glass attenuation, nodular opacities
Pulmonary function test Obstructive; normal diffusing capacity Restrictive; reduction in diffusing capacity
BAL Predominantly neutrophils Predominantly lymphocytes
Diagnosis Clinical, radiological and physiological criteria Usually requires tissue, best by surgical lung biopsy
Histolopathology 
Granular plugs obliterating the bronchiols with 
inflammation and scarring; sparing of the alveoli 
and alveolar ducts
Granular plugs of bronchiols, extending to alveoli; 
interstitial inflammation and fibrosis
Treatment Corticosteroids and immunosuppressive therapy Corticosteroids
Outcome Poor response to therapy; progressive disease with high mortality Good response to therapy; potentially reversible  
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brosis of the pulmonary venules and small veins, leading 
to progressive vascular obstruction and increased pull
monary capillary and arterial pressures. Patients typil
cally present several months after transplantation with 
progressive dyspnea on exertion and fatigue. The triad 
of pulmonary arterial hypertension, radiographic signs 
of pulmonary edema, and a normal pulmonary artery 
occlusion pressure strongly suggests the diagnosis, but 
it may not be present concurrently in all patients.107 
Surgical lung biopsy is the only way to confirm the 
diagnosis of pulmonary venolocclusive disease.107 
Because pulmonary venolocclusive disease has been 
reported in nonltransplant patients who have received 
radiation and chemotherapy and in patients with viral 
infections, it has been hypothesized that its occurrence 
after HSCT is a result of an infectious or toxic injury 
to the endothelium. Chemotherapeutic agents such as 
BCNU, mitomycin C, and bleomycin have been associl
ated with this process.108 
Arterial vasodilatation in the setting of fixed pull
monary venous resistance can markedly increase 
transcapillary hydrostatic pressure and precipitate or 
worsen pulmonary edema. Treatment of pulmonary 
venolocclusive disease with vasodilators is therefore 
potentially dangerous and must be initiated under 
close observation. Response to highldose corticostel
roid therapy has been anecdotally reported.106 The 
prognosis of patients with pulmonary venolocclusive 
disease is generally poor. 
Post-transplant lymphoproliferative disorder
Postltransplant lymphoproliferative disorder is an inl
frequent but serious complication following allogeneic 
HSCT. It represents an uncontrolled expansion of dol
norlderived, EBVlinfected B lymphocytes as the result 
of weakened cytotoxic T cell immunity. Major risk facl
tors for development of postltransplant lymphoprolifl
erative disorder include the use of unrelated or HLAl
mismatched related donors, T cellldepleted donor 
stem cells, and antilthymocyte globulin or monoclonal 
antilT cell antibodies for the prevention or treatment 
of GVHD.109 Although the overall incidence of postl
transplant lymphoproliferative disorder is only 1%, the 
incidence increases to 8% for those with two risk facl
tors and to 22% for those with three risk factors.109 The 
onset of postltransplant lymphoproliferative disorder 
is typically within the first 6 months and is most often 
characterized by involvement of lymph nodes, liver, and 
spleen. Pulmonary involvement occurs in about 20% of 
cases.110 Definitive diagnosis requires biopsy but quanl
titative EBV DNA monitoring by PCR techniques 
is emerging as a noninvasive diagnostic technique.111 
Treatment includes the administration of antilB cell 
monoclonal antibodies combined with a reduction in 
the dose of immunosuppressive agents.110,112 The pol
tential benefits of the infusion of in vitro–generated 
EBVlspecific cytotoxic T cells are under investigal
tion.112 Survival among HSCT recipients with postl
transplant lymphoproliferative disorder is considerably 
lower than that of solid organ transplant recipients and 
is particularly poor for those who had received HSCT 
for hematologic malignancies.110 
Pulmonary cytolytic thrombi
This is a rare noninfectious pulmonary complication 
following HSCT. Pulmonary cytolytic thrombi repl
resent pulmonary thrombi associated with infiltration 
by monocytes from donor and recipient origin in the 
small and medium pulmonary vessels. This disorder 
is reported exclusively following allogeneic HSCT 
in patients with other features of acute or chronic 
GVHD.113 The pathogenesis of pulmonary cytolytic 
thrombi is not known, but it may be a manifestation 
of GVHD. This condition has been primarily rel
ported in pediatric population, with onset between 8 
and 343 days (median 72 days) following HSCT.114,115 
The patients present with fever, cough, chest pain and 
dyspnea. Chest CT scan reveals multiple peripheral 
opacities consistent with pulmonary infarcts. Invasive 
pulmonary fungal infection is a major consideration 
with these findings; however this infection was never 
detected in the reported cases. The patients usually rel
spond to intensification of immunosuppressive therapy 
with clinical improvement in 1l2 weeks and radiologil
cal resolution over weeks or months.116 
Sarcoidosis
There are few reports that have described noncaseating 
granulomas suggestive of sarcoidosis following HSCT. 
Some of these reports suggest the possible transmission 
of sarcoidosis from the donor stem cells to the allogel
neic HSCT recipients.117l119 Another report described 
4 patients with sarcoidosis following HSCT (3 autolol
gous and 1 allogeneic HSCT) with no known history 
of sarcoidosis in the donor.119 Sarcoidosis in these rel
ports developed following stem cell engraftment a mean 
of 25 months (range 3l120 months) post HSCT.117l119 
This reaction may be due to an abnormal immunol
logical host response to common antigenic triggers. It 
is postulated that post HSCT lung environment may 
promote the development of nonlcaseating graunlomas 
by high levels of chemokines such as MCPl1,CCRI, 
CCR2 and ILl8.119 The reports of possible increased inl
cidence of sarcoidosis following HSCT underscore the 
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importance of diagnostic biopsies in HSCT recipients 
who develop mediastinal lymphadenopathy or pulmol
nary infiltrates. Symptomatic patients with sarcoidosis 
following HSCT respond well to corticosteroids and 
prognosis of these patients is good.119
Pulmonary fibrosis
There are patients who develop nonspecific pulmonary 
fibrosis that does not fit into any of the other nonlinl
fectious pulmonary complications following HSCT. 
Based on the authors’ observations, these patients are 
primarily long term survivors following allogeneic 
HSCT. They usually have dyspnea on exertion with 
cough, and develop frequent exacerbations consistent 
with acute bronchitis or pneumonia. The patients 
commonly have evidence of chronic GVHD, however 
it is usually quiescent. Pulmonary function tests usul
ally reveal restrictive pattern with reduction in diffusing 
capacity. Radiologically, there are fibrotic changes that 
tend to be in the lower lobes associated with areas of 
bronchiectasis. The exact etiology of this presentation 
is not clear, however it could be due to one or more 
of several factors. It is possible that this syndrome is a 
late manifestation of pulmonary drug toxicity, or due 
to chronic GVHD with scleroderma like changes, or 
due to recurrent aspiration associated with esophageal 
involvement by GVHD. Other possibilities include late 
stage of BOOP or IPS, or due to recurrent infections. 
These patients are usually managed by supportive meal
sure, and may require oxygen therapy and antibiotics 
when there are acute exacerbations. 
Asthma
Asthma and other allergic conditions such as allergic 
rhinitis may develop in allogeneic HSCT recipients 
from donors with atopy. This suggests the transfer of 
marrowlderived immune cells from allergic donors. 
In one report of HSCT from atopic donors to 5 nonl
atopic recipients, asthma developed in 4 of these pal
tients following HSCT.120 New onset of asthma followl
ing HSCT should be differentiated from BO, which is 
much more common in this patient population. 
Pulmonary alveolar proteinosis
Pulmonary alveolar proteinosis is pulmonary disease 
characterized by the accumulation of periodic acidl
Schiff stainlpositive amorphous material in the pulmol
nary alveolar space. Decreased clearance of the surfacl
tant proteins is considered one of the major causes of 
pulmonary alveolar proteinosis. Recent evidence sugl
gests that GMlCSF plays a role in the development of 
pulmonary alveolar proteinosis.121 There are few reports 
of acquired pulmonary alveolar proteinosis following 
HSCT.122,123 These cases were reported during the pel
riod of leukopenia after myeloablative conditioning for 
HSCT. The patients developed acute respiratory failure 
with diffuse alveolar pulmonary infiltrates. Prognosis of 
pulmonary alveolar proteinosis following HSCT is genl
erally poor.123 The role of interventions such as frequent 
BAL and administration of aerosolized recombinant 
GMlCSF to reverse the pulmonary disease in these pal
tients is not known. 
In conclusion, pulmonary complications remain 
an important problem following HSCT. The iml
proved transplant techniques and effective diagnosis 
and management of infectious complications have inl
creased the significance of nonlinfectious pulmonary 
conditions following HSCT. Future efforts should be 
directed to understanding the mechanisms leading to 
these complications and developing antilinflammatol
ry and immunomodulatory therapies that target these 
pathways.
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